权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Investigating the role of apoptosis regulation in cancer therapy-induced vascular toxicities

研究细胞凋亡调节在癌症治疗引起的血管毒性中的作用

基本信息

批准号：
10537996
负责人：
Mary Heather Celine Florido
金额：
$ 3.89万
依托单位：
HARVARD SCHOOL OF PUBLIC HEALTH
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-12-01 至 2025-11-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10537996
关键词：
ARHGEF5 gene Acute Adolescent Adult Affect Aftercare Age Aging Animals Antineoplastic Agents Apoptosis Apoptotic Atherosclerosis Automobile Driving BAX gene BCL2 gene Bax protein Biological Models Birth Blood Vessels Blood capillaries Cancer Patient Cancer Survivor Cell Death Cell physiology Cells Cellular Morphology Cellular Stress Chemotherapy and/or radiation Cisplatin Clinic Clinical Complement Cytochrome P450 Cytotoxic agent DNA Databases Detection Development Disease model Doxorubicin Elderly Endothelial Cells Exposure to External Beam Radiation Therapy FDA approved Future Gene Expression Gene Family Gene Proteins Health Heart Heart failure Human Hypertension Impairment In Vitro International Ionizing radiation Irreversible Toxicity Ischemia Knockout Mice Knowledge Laboratories Lead Life Link Longevity Malignant Neoplasms Measurement Measures Migration Assay Mitochondria Molecular Morphology Mus Normal tissue morphology Outcome Patients Peripheral Pharmaceutical Preparations Play Predisposition Prevention Protein Family Quality of life Radiation therapy Regimen Regulation Role Signal Pathway Smooth Muscle Myocytes Testing Therapeutic Thrombosis Tissues Toxic effect Tube Tyrosine Kinase Inhibitor VDAC1 gene Vascular Diseases Vascular Endothelial Cell Vascular Endothelium Vascular Smooth Muscle Vegf Inhibitor Work cancer cell cancer therapy cell injury cell type chemotherapy cytotoxic differentiation protocol effective therapy endothelial stem cell experience experimental study high risk human model improved in vivo induced pluripotent stem cell innovation mimetics neonate neoplastic cell pharmacovigilance prevent pro-apoptotic protein response screening targeted agent therapy development transcriptomics tumor tumor xenograft vascular stress venous thromboembolism

项目摘要

PROJECT SUMMARY Cancer treatments have evolved extensively over the past few decades, leading to vast improvements in overall survival and cure rates. However, the collateral damage inflicted upon healthy tissues by both targeted and cytotoxic agents frequently causes life-threatening irreversible toxicities. Some of the most common toxicities include therapy-induced vascular impairments such as atherosclerosis, heart failure, ischemia, acute thrombosis, and venous thromboembolism. Despite their widespread use, it is poorly understood how chemotherapies and ionizing radiation cause vascular toxicities. Most cancer therapies typically induce apoptosis (programmed cell death) by damaging common cellular components such as DNA or by blocking critical signaling pathways. Since vascular cells are also exposed to these agents at high concentrations, they could be vulnerable to therapy-induced apoptosis. However, the vasculature is comprised of several cell types including vascular endothelial and smooth muscle cells; it is unknown which cells are sensitive to anti-cancer agents and how they may contribute to long-term vascular dysfunction in patients. Using human induced pluripotent stem cells (hiPSCs) for in vitro disease modeling, we will investigate vascular toxicities in hiPSC- derived vascular endothelial cells and vascular smooth muscle cells. Utilizing robust differentiation protocols already established in our laboratory, we will rigorously test how the survival and function of these cells are affected by cancer treatments. We will also characterize the regulation of apoptosis in both vascular cell types by measuring apoptotic priming and expression of BCL-2 family proteins. Additionally, we will look at the functional and morphological changes that these cells undergo in response to cancer treatments that may contribute to vascular toxicities. We hypothesize that each vascular cell type possesses differential levels of apoptotic priming, and unique vulnerabilities to our panel of FDA-approved cancer therapies that drive therapy- induced vascular toxicities. Our studies will elucidate potential mechanisms and determine contributions of each cell type to vascular toxicities observed in cancer patients. Further, since aging is known to play a role in both vascular toxicity and regulation of apoptosis, we will investigate how age affects apoptotic priming and therapy sensitivity of vascular cells. We will replicate key experiments in mice at various life stages (neonate, juvenile, adult and advanced age) to validate our in vitro findings and elucidate how age affects the development of vascular toxicities. We will also utilize endothelial cell-specific BAX/BAK double knockout mice to determine the extent to which apoptosis blockade can ameliorate vascular toxicity induced by cancer treatment. Altogether, our work will test how apoptosis regulation affects the sensitivity of vascular cells to chemotherapy and radiation and how this is altered by aging. These results will lay the groundwork for improved therapy regimens in the clinic that may decrease long-term vascular toxicities in cancer patients.

项目总结